Muscle weakness linked to worse outcomes in lung disease patients

NCT ID NCT07178197

Completed Knowledge-focused Sponsor: Mersin University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study looked at 60 people with idiopathic pulmonary fibrosis (IPF) to see how common muscle loss (sarcopenia) is and how it affects their quality of life and disease progression. Researchers measured muscle strength, walking speed, lung function, and used a questionnaire to assess quality of life. The goal was to better understand the role of sarcopenia in IPF, which has not been well studied.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If the findings show a clear link, it could help doctors identify which IPF patients need extra support to maintain muscle strength and quality of life.
What could go wrong: This is a small, observational study that only looks at one point in time. It cannot prove cause and effect, and results may not apply to all IPF patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS (IPF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDIOPATHIC PULMONARY FIBROSIS (IPF) SARCOPENIA

Contacts and locations

Locations

Mersin University Faculty of Medicine

Mersin, Mersin, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.